viewFSD Pharma

FSD Pharma amends deal with Solarvest BioEnergy to accelerate progress of CBD project

The project is determining if its algal expression system can create pharmaceutical-grade cannabinoids

FSD Pharma -
To enable Solarvest to accelerate the pace of the research, FSD Pharma has issued a further 225,371 of its shares

FSD Pharma Inc (CSE:HUGE) (NASDAQ:HUGE), the specialty biotech, revealed it had amended its deal with Solarvest Bioenergy Inc designed to accelerate progress on the latter's CBD research project. 

As reported in May last year, Solarvest (CVE:SVS), based in Vancouver, British Columbia, holds a platform capable of producing health products from algae. 

READ: FSD Pharma strikes deal with Solarvest BioEnergy to develop pharmaceutical-grade cannabinoids from algae

The project, run by Solarvest, is determining if its algal expression system can create pharmaceutical-grade cannabinoids and has made progress towards this goal, said FSD.

Since this is a cost-intensive project, and, to enable Solarvest to accelerate the pace of the research, FSD Pharma has issued a further 225,371 of its shares to Solarvest, it also revealed in Tuesday's statement.

In addition, Solarvest has appointed the current president of FSD Pharma’s BioSciences division - Dr. Edward J. Brennan, Jr -  to its board of directors.

"The parties have also mutually agreed that Solarvest would benefit from the additional oversight of Dr. Brennan, who brings with him over 25 years of experience in leadership roles at major pharmaceutical companies and clinical research organizations and has a proven track record in drug development," said Ontario-headquartered FSD.

Significant potential benefits

There could be significant benefits to FSD Pharma.

If the CBD research project is successful, Solarvest is required to grant FSD an exclusive, worldwide license to develop and commercialize prescription drugs that can treat diseases affecting the central nervous system.

Solarvest will additionally provide FSD Pharma with a royalty fee on the sale or licensing of certain products derived from the project.

Solarvest owns numerous key patents. Its organic Omega-3 patent application has been filed and is pending in Europe, UK, USA, Canada, Japan, India, China, S. Korea, Hong Kong and Australia.

Being algae-based, the products are suitable for vegetarian and vegan diets.

Shares in FSD Pharma nudged up 2.66% to C$8.11 in early Toronto deals.

---Updates for share price--

Contact the author at [email protected]

Quick facts: FSD Pharma

Price: 2.73 CAD

Market: CSE
Market Cap: $40.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...


FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) CEO Raza Bokhari tells Proactive the group has submitted an Investigational New Drug (IND) application to the FDA for the use of its lead candidate FSD-201, or anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA), to treat...

on 09/10/2020

2 min read